Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The $69M go back starting in 2018 for the allergy test. The abc7 news headline is a little misleading because it makes it appear that it's all covid-19 tests related.
Here is another article that explains the situation, but also has misleading headline.
They don't say exactly how much they billed just for the covid tests.
They are both from Silicon Valley, not opposite sides of the country.
poster boy definition: a man who epitomizes or represents a specified quality, cause, etc
All I'm saying is that the DOJ, by going after Mark so vigorously in the first COVID-19 fraud that they are prosecuting, is giving a warning to others that this is serious stuff and that they are making it a priority to prosecute covid-19 related fraud.
And once the SEC and DOJ had their nose under the Arrayit tent because of the covid investigation, they found other unsavory stuff.
I'm not saying that Mark is innocent or guilty of the charges, that's up to the judge and jury to decide based on the evidence that the DOJ/SEC presents.
DOJ really wants to make Mark their poster boy to deter others
Thanks!
Alyssa, do you know what's going on with the Taub case?
TIA
And what would happen to Arrayit?
Then after that he has the initial Case Management Conference set for 12/10/2020 10:00 AM in San Jose, Courtroom 4, 5th Floor before Hon. Edward J. Davila.
In the other civil case Securities and Exchange Commission v. Schena
https://www.pacermonitor.com/public/case/36421484/Securities_and_Exchange_Commission_v_Schena
Sorry. I didn't know it had been postponed to 11/15 at the DOJ's request
Thanks for the update. I wasn't aware it had moved to 11/15 at the DOJ's request
Next Proceeding: Preliminary Examination set for October 15, 2020 at 10:30am at the San Jose Courthouse, Courtroom 5, 280 South 1st Street, San Jose, VA 95113 before Magistrate Judge Nathanael Cousins.
Arrayit was never in the list of "commercial manufacturers of serological tests".
They were in the list of "Laboratories that have notified FDA that they have validated and intend to offer serology tests as set forth in Section IV.D:"
Yes I agree.
The SEC/DOJ originally investigated Arrayit because of the covid test and the posts from people saying that the test was approved by the FDA. It's ironic that now the FDA won't regulate the tests anymore, but the SEC/DOJ found other stuff when they put their nose under the tent.
I'm just pointing out that with this change, the FDA won't regulate the LDT tests like Arrayit's coronavirus test anymore (and I presume the ovarian cancer test either) And they won't need the EUA for the coronavirus from the FDA anymore. The tests will be overseen by HHS’s Centers for Medicare and Medicaid Services, and the FDA will still have the authority to take a bad test off the market.
I don't know what impact, if any, this change will have in the criminal case.
Trump administration bars FDA from regulating some laboratory tests, including for coronavirus.
Administration officials said the decision, announced Wednesday on the website of the Department of Health and Human Services, was made for legal reasons.They said the FDA lacks the authority to regulate laboratory-developed tests — a significant part of the market. The agency, they said, can only obtain that through a formal rulemaking process.
The tests affected are those developed by and used at laboratories regulated under the Clinical Laboratory Improvement Amendments program, which is overseen by HHS’s Centers for Medicare and Medicaid Services. Such labs are in big academic medical centers, smaller commercial laboratories and
https://www.washingtonpost.com/health/2020/08/20/trump-fda-tests-coronavirus/?hpid=hp_hp-top-table-main_viruslabs811pm%3Ahomepage%2Fstory-ans
I've never said that this serious matter is "just a bump in the road". Those are your words.
I don't think on the 11th they will be sentencing.
Sloan, let's hope so. The new website for Theralink looks very professional by the way.
The question was whether the company itself or its management were in disrepute. The disrepute was brought upon it by its management.
Not whether the company can be sued.
Two Friends in Texas Were Tested for Coronavirus. One Bill Was $199. The Other? $6,408.
It’s an example of the unpredictable way health prices can vary for patients who receive identical care.
Such discrepancies arise from a fundamental fact about the American health care system: The government does not regulate health care prices.
We the shareholders own the company. The company in of itself is not of disrepute. It's the management that brought shame and dishonor to the company.
If a complete new set of management took over and cleaned up the business and commercialized the tests in the pipeline they might have a future. Maybe.
Another possibility why they are off the FDA list could be that the status of the CLIA lab may be in question. Julie Taguchi was the lab director and she, according to the complaint against her, may not have had the appropriate qualification to be the lab director.
And someone posted this from Mark's attorney, Todd Pickles" which seem to indicate that Mark wants to be the lab director?
At least Mark seems to have found a good lawyer
https://www.gtlaw.com/en/professionals/p/pickles-todd-a
#19 does say "Arrayit has issued several billion shares of stock"
But the issued and outstanding shares O/S is 1.1 billion, not "several" billion.
The dilution happened in 2015-16 from 50M to 1.1billion
I don't know how much TF charges.
Does KBLB have a multiplex allergy blood test?
About the allergy test, I think that Mark could scientifically defend the allergy test testing 120 allergens simultaneously. Thermo Fisher has developed a test called ImmunoCap Isac 112 that uses microarrays to test for 112 allergens. It has the CE label authorizing its use in Europe, other countries around the world sell it too, but not in the USA because they have not submitted it for FDA approval and is not an LDT test like Arrayit's.
The way Arrayit marketed the test is a different story.
Interesting rebroadcast:
https://investorshub.advfn.com/boards/replies.aspx?msg=154808528
Where did you find the Defendant's Brief? TIA
From the complaint
Agreed.
Someone bought 2,222,222 shares at 0.009 today = $2,000
It's an off-exchange :)
ARYC used to be listed on the OTCQB years ago, before the dilution brought it under 0.01 and it did not qualify anymore
OTCQB LISTING REQUIREMENTS:
http://www.legalandcompliance.com/securities-law/otc-market-compliance/otc-markets-listing-requirements/otcqb-listing-requirements/
If I'm reading this correctly, Avant alone will initially get 4.4 billion shares of OncBioMune's common stock. So a RS is definitely a strong possibility
June 8, 2020
"Upon the filing of an amendment to OncBioMune's Articles of Incorporation to increase its authorized common stock, which is expected to occur within 45 days, the shares of preferred stock issued to Avant shall automatically convert into approximately 4.4 billion shares of OncBioMune's common stock."
https://www.accesswire.com/593012/OncBioMune-Announces-Closing-of-Asset-Purchase-Agreement-with-Avant-Diagnostics